Technology And Equipment Tenders

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Natalizumab (Exclusively in the Dafo Injection Solution, Atc L04aa23 (Obo) for the Period 09/01/24 - 08/31/26

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Abatacept, Atc L04aa24 (Obo) for the Period September 1St, 2024 - August 31St, 2026

Conclusion of Non-Exclusive Discount Agreements in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredients Mentioned with the Possibility of Conclusion Within the Framework of the So-Called Open House Procedure.

Accompanying Agency for the Federal Program for Adapting Urban and Rural Areas to Climate Change - 4Th Tranche

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Lidocaine, Atc N01bb02 (Obg) for the Period September 1St, 2024 - August 31St, 2026

Delivery, Installation and Maintenance of a High-Field Mri (9T)

Conclusion not Excluding Drug Discount Agreement. According to Section 130A Paragraph 8 Sgb V through an Open House Model for the Active Ingredient Rasagiline (Atc Code According to Who: N04bd02)

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Milnacipran, Atc N06ax17 (Obg) for the Period September 1St, 2024 - August 31St, 2026

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Triptorelin, Atc L02ae04 (Obo) for the Period September 1St, 2024 - August 31St, 2026

A.6000.223364, Tu Darmstadt; 3209 New Building for the Mathematics Institute Building